Medivation Names Stephen Kelsey Senior Vice President of New Projects

Medivation Names Stephen Kelsey Senior Vice President of New Projects 
SAN FRANCISCO, CA -- (Marketwired) -- 05/13/13 --  Medivation, Inc.
(NASDAQ: MDVN) today announced that Stephen M. Kelsey, M.D.,
F.R.C.P., F.R.C.Path. will join Medivation in the newly-created
position of senior vice president of new projects, reporting to Dr.
David Hung, M.D., Medivation's president and chief executive officer. 
"Stephen Kelsey is an extremely well-respected and prolific product
development executive with an impressive track record of successfully
developing Perjeta, Kadcyla and Erivedge and playing a significant
role in the development of blockbuster products such as Rituxan
(chronic lymphocytic leukemia) and Herceptin (TCH regimen)," said
David Hung, M.D., president and chief executive officer of
Medivation, Inc. "We are delighted to have him as part of our team
and to leverage his expertise as we accelerate our current efforts to
expand our clinical portfolio and drive new products into the
clinic." 
"Medivation's productive internal research efforts to date have
generated a number of intriguing compounds in areas that address
large markets with significant unmet needs," said Stephen M. Kelsey,
M.D., F.R.C.P., F.R.C.Path. "I am excited to join the team to help
Medivation advance a clinical portfolio of innovative and diverse
product candidates." 
Stephen M. Kelsey joins Medivation from Geron Corporation where he
served as the executive vice president, research & development and
chief medical officer. From 2009 to 2011 he served as executive vice
president and chief medical officer, oncology at Geron. From 2002 to
2009, Dr. Kelsey held various positions at Genentech, Inc., most
recently as vice president, clinical hematology/oncology, where he
was responsible for the oncology late stage development portfolio
including Rituxan(R), Herceptin(R), Tarceva(R), Perjeta(R),
Kadcyla(TM), Erivedge(R) and five additional development products in
solid tumors and hematologic malignancies. From 2000 to 2002, Dr.
Kelsey was the director of clinical affairs at Pharmacia Corporation
(SUGEN, Inc.), where he was responsible for Sutent(R), and director
of global clinical development (oncology) at Pharmacia Corporation in
Milan, Italy. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B.,
Ch.
B., and Doctorate of Medicine (M.D.) degrees from the University
of Birmingham in the United Kingdom.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at
www.medivation.com. 
Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900